Research Article
Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment
Table 1
Demographical and clinical characteristics of subjects.
| | | SC | SVR | NR | value | | | | | |
| | Age, median (range) | 58 years (41–67) | 63 years (47–67) | 62 years (50–69) | 0.047 (Kruskal-Wallis) | | Gender, number (%) | | | | | | Male | 14 (93%) | 21 (95%) | 18 (100%) | 0.57 (Chi-squared test) | | Female | 1 (7%) | 1 (5%) | 0 | | Race, number (%) | | | | | | White | 11 (73%) | 15 (68%) | 13 (72%) | 0.975 (Chi-squared test) | | Black | 2 (13%) | 4 (18%) | 2 (11%) | | Other or mixed | 2 (13%) | 3 (14%) | 3 (17%) | | Fib 4, median (range) | 1.34 (0.78–3.74) | 1.51 (0.85–3.69) | 3.395 (1.02–14.18) |
0.001 (Kruskal-Wallis) | | Age adjusted Charlson score, median (range) | 2 (0–6) | 3 (1–9) | 4 (2–10) | <0.001 (Kruskal-Wallis) | | Prescription NSAID use, number (%) | 4 (27%) | 5 (23%) | 4 (22%) | 0.948 (Chi-squared test) | | Statin use, number (%) | 3 (20%) | 3 (14%) | 2 (11%) | 0.762 (Chi-squared test) | | HCG genotype, number (%) | | | | | | 1 | NA | 20 (91%) | 9 (50%) | 0.027 (Chi-squared test) | | 2 | NA | 2 (9%) | 5 (28%) | | 3 | NA | 0 | 3 (17%) | | 4 | NA | 0 | 1 (5%) | | HCV treatment, type | | | | | | Ribavirin/peg-interferon | NA | 10 (45%) | 13 (72%) | 0.116 (Fisher exact test) | | Ribavirin/peg-interferon + protease inhibitor | NA | 12 (55%) | 5 (28%) | | Time since last interferon treatment, median (range) | NA | 721.5 days (217–2264) | 972 days (357–2219) | 0.348 (Mann-Whitney) | | Weeks of interferon, median (range) | NA | 48.0 | 21.5 | 0.003 (Mann-Whitney) |
|
|
NA: not available.
|
